Drug intelligence / Profile preview

dilazep

Development stage
Unknown
Lead developer
Kowa
Modality
Small Molecules
Administration
Oral
01

Overview

Dilazep is a small molecule vasodilator that acts primarily as an adenosine reuptake inhibitor. It exhibits antiplatelet, antianginal, and vasodilator properties. By inhibiting the cellular uptake of adenosine via equilibrative nucleoside transporter 1 (SLC29A1), it increases extracellular adenosine concentrations, leading to vasodilation and inhibition of platelet aggregation. Dilazep also improves blood flow in coronary and renal vessels, protects cardiac muscle, reduces proteinuria in renal dysfunction, and is used clinically for the treatment of ischemic heart disease (including angina), cerebral ischemia, and certain renal disorders[1][3][4][5][7]. Its mechanism includes reducing thromboxane B2 formation by impairing arachidonic acid release from platelet membranes[6].

Brand names
Comelian KowaDILAZEP HYDROCHLORIDE TABLETS 100mg "TOWA"
Other names
dilazepDilazepamDilazepumBiopropazepan Trimethoxybenzoate
02

Targets

ENT1 (Solute carrier family 29 member 1)ENT2 (Equilibrative nucleoside transporter 2)

Beyond the preview

Go deeper on dilazep.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dilazep.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call